Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nano-formulation curcumin as adjuvant to XELOX or FOLFOX in metastatic colorectal cancer
IRCT20200408046990N7Phase 2Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, triple-blind trial of curcumin in metastatic colon cancer (mCRC) (2 arms), sponsored by Mashhad University of Medical Sciences. Started Feb 2021; status: completed.
02
Drugs
curcumin
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on IRCT20200408046990N7.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200408046990N7.